ArticleInternational ophthalmology2023
Brain-derived neurotrophic factor levels and macular ganglion cell-inner plexiform layer thickness in macular telangiectasia type 2.
Article in International ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Clinical characteristics, imaging features, and treatment outcomes of macular telangiectasia type 2: a comprehensive meta-analysis.Scientific reports · 2026Pooled it
- Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial.Neural regeneration research · 2024Article
- Neurotrophins and Trk Neurotrophin Receptors in the Retina of Adult Killifish (International journal of molecular sciences · 2024Article
- NMOSD IgG Impact Retinal Cells in Murine Retinal Explants.Current issues in molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine brain-derived neurotrophic factor (BDNF) levels in the serum and aqueous humor (AH) and assess the relationship between BDNF levels and the thickness of the macular ganglion cell-inner plexiform layer (GCIPL) in macular telangiectasia type 2 (MacTel).
methodsThis study included 25 patients with MacTel (MacTel group) and 25 control subjects (control group). The levels of BDNF in the serum and AH were tested using an enzyme-binding immunosorbent assay. GCIPL thickness was measured by segmentation analysis using optical coherence tomography (OCT).
resultsThere was no significant difference in the mean serum BDNF levels between the MacTel and control groups (p = 0.145). The average BDNF level in the AH was significantly lower than that in the control group (p = 0.026). OCT segmentation analyses revealed that the minimum GCIPL thickness was significantly lower in the MacTel group than in the control group (p = 0.039). In the correlation analysis of BDNF levels with GCIPL thickness, significant correlations existed between the BDNF level of the AH and minimum GCIPL thickness in the MacTel group.
conclusionThe concentration of BDNF in the AH was decreased in the MacTel group, and this reduction was related to the minimum GCIPL thickness. The low BDNF levels detected in the MacTel group may have resulted in thinning of the GCIPL due to the loss of retinal ganglion cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.